



Search terms : (3) (092054)@PN,CD

【印出】

Patent/Publication Number 325472

Title A pharmaceutical composition for preventing cancer comprising 2-(1-hydroxyethyl)-5-hydroxynaphto[2,3-b]furan-4,9-dione

Issued/Publication Date 1998/01/21

Application Date 1993/07/09

Application Number 082105480

Certification Number 092054

IPC A61K-031/34

Inventor KAMITA SHINICHI JP;
TOKUTA HARUKUNI JP;
HIRAI KEIICHI JP;
HATAKENAKA HEIHACHI JP

Applicant NIPPON TAHIBO KKJP

Priority Number 19920918JP19920249340
19930224JP19930035251

Abstract A pharmaceutical composition for preventing cancer, which comprises 2-(1-hydroxyethyl)-5-hydroxynaphto[2,3-b]furan-4,9-dione of the following formula (1) as an active ingredient (1).

Individual F

Patent Right Change

Application Number	082105480
Date of Update	20101210
Granting of a license	NO
Registration of patent mortgage	NO
Transfer of patent right	NO
Succession of patent right	NO
Registration of patent trust	NO
Opposition filed	NO
Request for Invalidation filed	NO
Date of lapse	
Patent revoked	
Date of grant	19980121
Scheduled expiry date	20130708
Due date of annual fee	20120120
Years of annuities paid	14





Search terms: (3) (092054)@PN,CD

[【印出】](#)

公告本

27650



325478




圖 4




圖 5




圖 6




圖 7





圖 8



325472

圖 9




圖 10




圖 11




圖 12





圖 13



325479

圖 14




圖 15




圖 16




圖 17




圖 18





圖 19



325472

圖 20








圖 21




325472




325472




325472




325472




325472



325472



325472



Information on this system is for reference only, it cannot be used as grounds for approval or rejection. In all instances of discrepancy, official publication from TIPO shall prevail and should be consulted.